Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate some of the excess demand, the Company had agreed to raise an additional $0.96 million on the same terms as the Offer (“Follow-On Placement”).
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal